Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518385-26-01

Acronym

29BRC23.0160

Enrollment

140

Registered

2025-10-07

Start date

2025-12-18

Completion date

Unknown

Last updated

2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polymyalgia Rheumatica (PMR)

Brief summary

The primary outcome is a PMR-AS (CRP) ≤10 (no flare) without steroids at week 24.

Detailed description

PMR-AS (CRP) ≤10 (no flare) without steroids at week 24, PMR-AS (CRP) ≤10 (no flare) without steroids at week 12, PMR-AS (CRP) ≤10 (no flare) without steroids at week 12, PMR-AS (CRP) ≤10 (no flare) without steroids at week 24, PMR-AS (CRP) ≤10 (no flare) without steroids at week 12, Exploratory End Points (see synopsis), PMR-AS (CRP) ≤10 (no flare) without steroids at week 36, PMR-AS (CRP) ≤10 (no flare) without steroids at week 36, PMR-AS (CRP) ≤10 (no flare) without steroids at week 36

Interventions

DRUGOlumiant 4 mg film-coated tablets

DRUGOlumiant 2 mg film-coated tablets

DRUGtablets containing placebo to match 2 mg baricitinib

DRUGtablets containing placebo to match 4 mg baricitinib

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
PMR-AS (CRP) ≤10 (no flare) without steroids at week 24, PMR-AS (CRP) ≤10 (no flare) without steroids at week 12, PMR-AS (CRP) ≤10 (no flare) without steroids at week 12, PMR-AS (CRP) ≤10 (no flare) without steroids at week 24, PMR-AS (CRP) ≤10 (no flare) without steroids at week 12, Exploratory End Points (see synopsis), PMR-AS (CRP) ≤10 (no flare) without steroids at week 36, PMR-AS (CRP) ≤10 (no flare) without steroids at week 36, PMR-AS (CRP) ≤10 (no flare) without steroids at week 36	—

Measure

Time frame

—

Primary

Measure	Time frame
The primary outcome is a PMR-AS (CRP) ≤10 (no flare) without steroids at week 24.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026